Skip to main content
. Author manuscript; available in PMC: 2021 May 25.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2018 Aug 29;18(12):788–795.e2. doi: 10.1016/j.clml.2018.08.009

Figure 3.

Figure 3

PV-Related Treatment at Enrollment. For “Other Agents,” Patients Could Be Counted in More Than One Category; Treatment Included Ruxolitinib (3.8%), Anagrelide (2.0%), Interferons (1.4%), and Other (1.2%). Treatment Was Unknown for 2 Patients